Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

UK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead compound, a first-in-class cancer treatment. The company ...